Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomolecules ; 13(9)2023 09 20.
Artigo em Inglês | MEDLINE | ID: mdl-37759819

RESUMO

Vascular calcification (VC) is a common complication in patients with chronic kidney disease which increases their mortality. Although oxidative stress is involved in the onset and progression of this disorder, the specific role of some of the main redox regulators, such as catalase, the main scavenger of H2O2, remains unclear. In the present study, epigastric arteries of kidney transplant recipients, a rat model of VC, and an in vitro model of VC exhibiting catalase (Cts) overexpression were analysed. Pericalcified areas of human epigastric arteries had increased levels of catalase and cytoplasmic, rather than nuclear runt-related transcription factor 2 (RUNX2). In the rat model, advanced aortic VC concurred with lower levels of the H2O2-scavenger glutathione peroxidase 3 compared to controls. In an early model of calcification using vascular smooth muscle cells (VSMCs), Cts VSMCs showed the expected increase in total levels of RUNX2. However, Cts VMSCs also exhibited a lower percentage of the nucleus stained for RUNX2 in response to calcifying media. In this early model of VC, we did not observe a dysregulation of the mitochondrial redox state; instead, an increase in the general redox state was observed in the cytoplasm. These results highlight the complex role of antioxidant enzymes as catalase by regulation of RUNX2 subcellular location delaying the onset of VC.


Assuntos
Insuficiência Renal Crônica , Calcificação Vascular , Humanos , Animais , Ratos , Catalase , Subunidade alfa 1 de Fator de Ligação ao Core/genética , Peróxido de Hidrogênio , Oxirredução
2.
Kidney Int ; 90(1): 77-89, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-27165819

RESUMO

Bone loss and increased fractures are common complications in chronic kidney disease. Because Wnt pathway activation is essential for normal bone mineralization, we assessed whether Wnt inhibition contributes to high-phosphorus-induced mineralization defects in uremic rats. By week 20 after 7/8 nephrectomy, rats fed a high-phosphorus diet had the expected high serum creatinine, phosphorus, parathyroid hormone, and fibroblast growth factor 23 (FGF23) levels and low serum calcium. There was a 15% reduction in tibial mineral density and a doubling of bone cortical porosity compared to uremic rats fed a normal-phosphorus diet. The decreases in tibial mineral density were preceded by time-dependent increments in gene expression of bone formation (Osteocalcin and Runx2) and resorption (Cathepsin K) markers, which paralleled elevations in gene expression of the Wnt inhibitors Sfrp1 and Dkk1 in bone. Similar elevations of Wnt inhibitors plus an increased phospho-ß-catenin/ß-catenin ratio occurred upon exposure of the osteoblast cell line UMR106-01 either to uremic serum or to the combination of parathyroid hormone, FGF23, and soluble Klotho, at levels present in uremic serum. Strikingly, while osteoblast exposure to parathyroid hormone suppressed the expression of Wnt inhibitors, FGF23 directly inhibited the osteoblastic Wnt pathway through a soluble Klotho/MAPK-mediated process that required Dkk1 induction. Thus, the induction of Dkk1 by FGF23/soluble Klotho in osteoblasts inactivates Wnt/ß-catenin signaling. This provides a novel autocrine/paracrine mechanism for the adverse impact of high FGF23 levels on bone in chronic kidney disease.


Assuntos
Descalcificação Patológica/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Osteoblastos/metabolismo , Insuficiência Renal Crônica/complicações , Via de Sinalização Wnt , Animais , Biomarcadores/sangue , Biomarcadores/metabolismo , Calcificação Fisiológica , Cálcio/sangue , Catepsina K/metabolismo , Linhagem Celular Tumoral , Subunidade alfa 1 de Fator de Ligação ao Core/metabolismo , Descalcificação Patológica/etiologia , Modelos Animais de Doenças , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/farmacologia , Glucuronidase/metabolismo , Glucuronidase/farmacologia , Humanos , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Proteínas Klotho , Masculino , Proteínas de Membrana/metabolismo , Osteoblastos/efeitos dos fármacos , Osteocalcina/metabolismo , Hormônio Paratireóideo/sangue , Fósforo/sangue , Fósforo/metabolismo , Fósforo na Dieta/efeitos adversos , Porosidade , Ratos , Ratos Wistar , Insuficiência Renal Crônica/metabolismo , Tíbia/metabolismo , Tíbia/patologia , Uremia/complicações , Uremia/metabolismo , Proteínas Wnt/antagonistas & inibidores , Proteínas Wnt/metabolismo , Via de Sinalização Wnt/efeitos dos fármacos , beta Catenina/sangue
3.
Bone ; 84: 160-168, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26769003

RESUMO

Vascular calcification remains one of the main factors associated to morbidity and mortality in both ageing and chronic kidney disease. Both hyperphosphataemia, a well-known promoter of vascular calcification, and abnormal processing defects of lamin A/C have been associated to ageing. The main aim of this study was to analyse the effect of phosphorus load in the differential expression pattern of genes and proteins, particularly of lamin A/C, which are involved in phenotypic change of the vascular smooth muscle cells to osteoblast-like cells. The in vivo study of the calcified abdominal aortas from nephrectomized rats receiving a high phosphorus diet showed among others, a repression of muscle related proteins and overexpression of lamin A/C. Similar results were observed in vitro, where primary vascular smooth muscle cells cultured in calcifying medium showed increased expression of prelamin A and lamin A and abnormalities in the nuclear morphology. Co-immunoprecipitation assays showed novel and important physical interactions between lamin A and RUNX2 during the process of calcification. In fact, the knockdown of prelamin A and lamin A inhibited the increase of Runx2, osteocalcin and osteopontin gene expression, calcium deposition, nuclear abnormalities and the RUNX2 protein translocation into the nucleus of the cell. These in vivo and in vitro results highlight the important role played by lamin A in the process of vascular calcification.


Assuntos
Falência Renal Crônica/complicações , Lamina Tipo A/metabolismo , Fósforo/efeitos adversos , Calcificação Vascular/etiologia , Calcificação Vascular/metabolismo , Animais , Aorta/efeitos dos fármacos , Aorta/patologia , Biomarcadores/sangue , Células Cultivadas , Subunidade alfa 1 de Fator de Ligação ao Core/metabolismo , Dieta , Técnicas de Silenciamento de Genes , Imunoprecipitação , Masculino , Modelos Biológicos , Ratos Wistar , Espectrometria de Massas em Tandem , Calcificação Vascular/sangue
4.
Am J Physiol Endocrinol Metab ; 307(12): E1085-96, 2014 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-25336523

RESUMO

Despite the presence of vitamin D receptor (VDR) in endothelial cells, the effect of vitamin D on endothelial function is unknown. An unbalanced production of vasoactive endothelial factors such as nitric oxide (NO) or endothelin-1 (ET-1) results in endothelial dysfunction, which can alter the normal cardiovascular function. Present experiments were devoted to assess the effect of active vitamin D (calcitriol) on the synthesis of endothelial vasoactive factors. The results were that, in cells, calcitriol increased ET-1 and NO productions, which were measured by ELISA and fluorimetric assay, respectively. Calcitriol also increased endothelin-converting enzyme-1 (ECE-1) and endothelial-nitric oxide synthase (eNOS) activities, their mRNA (qPCR), their protein expressions (Western-blot), and their promoter activities (transfection assays). Calcitriol did not change prepro-ET-1 mRNA. The effect was specific to VDR activation because when VDR was silenced by siRNA, the observed effects disappeared. Mechanisms involved in each upregulation differed. ECE-1 upregulation depended on AP-1 activation, whereas eNOS upregulation depended directly on VDR activation. To evaluate the in vivo consequences of acute calcitriol treatment, normal Wistar rats were treated with a single ip injection of 400 ng/kg calcitriol and euthanized 24 h later. Results confirmed those observed in cells, that production and expression of both factors were increased by calcitriol. Besides, calcitriol-treated rats showed a slight rise in mean blood pressure, which decreased when pretreated with FR-901533, an ECE-1 antagonist. We conclude that calcitriol increases the synthesis of both ET-1 and NO in endothelial cells. However, the ET-1 upregulation seems to be biologically more relevant, as animals acutely treated with calcitriol show slight increases in blood pressure.


Assuntos
Calcitriol/farmacologia , Células Endoteliais/efeitos dos fármacos , Endotelinas/metabolismo , Óxido Nítrico/metabolismo , Animais , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/genética , Células Cultivadas , Células Endoteliais/metabolismo , Células Endoteliais/fisiologia , Enzimas Conversoras de Endotelina , Humanos , Masculino , Metaloendopeptidases/genética , Metaloendopeptidases/metabolismo , Óxido Nítrico Sintase Tipo III/genética , Óxido Nítrico Sintase Tipo III/metabolismo , Ratos , Ratos Wistar , Receptores de Calcitriol/genética , Receptores de Calcitriol/metabolismo , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/genética
5.
Science ; 345(6196): 1251343, 2014 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-25082706

RESUMO

Long interspersed nuclear element-1 (L1) retrotransposons are mobile repetitive elements that are abundant in the human genome. L1 elements propagate through RNA intermediates. In the germ line, neighboring, nonrepetitive sequences are occasionally mobilized by the L1 machinery, a process called 3' transduction. Because 3' transductions are potentially mutagenic, we explored the extent to which they occur somatically during tumorigenesis. Studying cancer genomes from 244 patients, we found that tumors from 53% of the patients had somatic retrotranspositions, of which 24% were 3' transductions. Fingerprinting of donor L1s revealed that a handful of source L1 elements in a tumor can spawn from tens to hundreds of 3' transductions, which can themselves seed further retrotranspositions. The activity of individual L1 elements fluctuated during tumor evolution and correlated with L1 promoter hypomethylation. The 3' transductions disseminated genes, exons, and regulatory elements to new locations, most often to heterochromatic regions of the genome.


Assuntos
Elementos de DNA Transponíveis , Elementos Nucleotídeos Longos e Dispersos , Neoplasias/genética , Transdução Genética , Carcinogênese/genética , Cromatina/química , Éxons , Genoma Humano , Humanos , Mutagênese Insercional , Translocação Genética
6.
J Clin Invest ; 124(7): 2988-3002, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24911144

RESUMO

Both maternal and offspring-derived factors contribute to lifelong growth and bone mass accrual, although the specific role of maternal deficiencies in the growth and bone mass of offspring is poorly understood. In the present study, we have shown that vitamin B12 (B12) deficiency in a murine genetic model results in severe postweaning growth retardation and osteoporosis, and the severity and time of onset of this phenotype in the offspring depends on the maternal genotype. Using integrated physiological and metabolomic analysis, we determined that B12 deficiency in the offspring decreases liver taurine production and associates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) axis. Taurine increased GH-dependent IGF1 synthesis in the liver, which subsequently enhanced osteoblast function, and in B12-deficient offspring, oral administration of taurine rescued their growth retardation and osteoporosis phenotypes. These results identify B12 as an essential vitamin that positively regulates postweaning growth and bone formation through taurine synthesis and suggests potential therapies to increase bone mass.


Assuntos
Desenvolvimento Ósseo/fisiologia , Crescimento/fisiologia , Taurina/biossíntese , Vitamina B 12/metabolismo , Animais , Densidade Óssea/fisiologia , Feminino , Transtornos do Crescimento/etiologia , Transtornos do Crescimento/metabolismo , Hormônio do Crescimento/metabolismo , Fator de Crescimento Insulin-Like I/biossíntese , Fator Intrínseco/deficiência , Fator Intrínseco/genética , Fígado/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Osteoporose/etiologia , Osteoporose/metabolismo , Gravidez , Complicações na Gravidez/genética , Complicações na Gravidez/metabolismo , Efeitos Tardios da Exposição Pré-Natal , Fator de Transcrição STAT5/metabolismo , Taurina/administração & dosagem , Deficiência de Vitamina B 12/complicações , Deficiência de Vitamina B 12/genética
7.
Int J Biochem Cell Biol ; 45(7): 1255-64, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23579096

RESUMO

Activation of the insulin growth factor receptor-1 signaling pathways has been largely related to the aging process. Amadori products are produced in pathological conditions such as diabetes and aging, and are potentially involved in diabetic nephropathy or age-associated decline of renal function. We hypothesize that Amadori products induce senescence in primary human mesangial cells through the activation of IGF-1 receptor and investigate, in the present work, the intracellular mechanism involved after this activation. We treated cultured human mesangial cells with glycated albumin, one of the most abundant Amadori product, and senescence was assessed by determining the senescence associated ß-galactosidase activity and the expression of the cell cycle regulators p53 and p21. We demonstrated that prolonged exposition (more than 24h) to glycated albumin induced senescence and, in parallel, incremented the release of IGF-1 and the activation of the IGF-1 receptor. Inhibition of the IGF-1 activation prevented the GA induced senescence. Activation of IGF-1R, after GA addition, promoted a reduction in the catalase content through the constitutive activation of Ras and erk1/2 proteins which were, in turn, responsible of the observed GA-induced senescence. In conclusion, we propose that the Amadori product, glycated albumin, promotes premature cell senescence in mesangial cells through the activation of the IGF-1 receptor and the subsequent reduction in the antioxidant enzyme catalase.


Assuntos
Catalase/biossíntese , Senescência Celular/fisiologia , Fator de Crescimento Insulin-Like I/metabolismo , Receptor IGF Tipo 1/metabolismo , Albumina Sérica/farmacologia , Células Cultivadas , Regulação para Baixo , Mesângio Glomerular/citologia , Mesângio Glomerular/metabolismo , Produtos Finais de Glicação Avançada , Humanos , Células Mesangiais/metabolismo , Transdução de Sinais/efeitos dos fármacos , Proteína Supressora de Tumor p53/biossíntese , beta-Galactosidase/efeitos dos fármacos , beta-Galactosidase/metabolismo , Proteínas rho de Ligação ao GTP/biossíntese , Albumina Sérica Glicada
8.
Endocrinology ; 153(4): 1627-37, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22334717

RESUMO

Phosphate load accelerates the progression of secondary hyperparathyroidism (sHPT). In advanced stages of sHPT, there is a marked hyperplasia and resistance to classical regulatory endocrine factors such as calcium, calcitriol, or fibroblast growth factor 23 (FGF23), which suppresses PTH secretion by an ERK-dependent mechanism. Nephrectomized rats were fed with a high- or normal-phosphorus diet for different periods of time to induce sHPT. Biochemical parameters, parathyroid gland microarrays, quantitative real-time PCR, and immunohistochemistry (ERK/phospho-ERK) were performed. To test the role of dual-specificity phosphatases (Dusp) on parathyroid gland regulation, normal parathyroid glands were cultured with FGF23 and Dusp. Uremic rats fed with a high-phosphorus diet showed more severe sHPT, higher serum FGF23 levels and mortality, and decreased parathyroid Klotho gene expression. In all stages of sHPT, parathyroid microarrays displayed a widespread gene expression down-regulation; only a few genes were overexpressed, among them, Dusp5 and -6. In very severe sHPT, a significant reduction in phospho-ERK (the target of Dusp) and a significant increase of Dusp5 and -6 gene expression were observed. In ex vivo experiments with parathyroid glands, Dusp partially blocked the effect of FGF23 on PTH secretion, suggesting that Dusp might play a role in parathyroid regulation. The overexpression of Dusp and the inactivation of ERK found in the in vivo studies together with the ex vivo results might be indicative of the defense mechanism triggered to counteract hyperplasia, a mechanism that can also contribute to the resistance to the effect of FGF23 on parathyroid gland observed in advanced forms of chronic kidney disease.


Assuntos
Fosfatases de Especificidade Dupla/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Glândulas Paratireoides/metabolismo , Glândulas Paratireoides/patologia , Uremia/metabolismo , Uremia/patologia , Animais , Células Cultivadas , Modelos Animais de Doenças , Fosfatases de Especificidade Dupla/farmacologia , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Fatores de Crescimento de Fibroblastos/farmacologia , Perfilação da Expressão Gênica , Glucuronidase/metabolismo , Hiperparatireoidismo Secundário/genética , Hiperparatireoidismo Secundário/metabolismo , Hiperplasia/metabolismo , Hiperplasia/patologia , Proteínas Klotho , Masculino , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Glândulas Paratireoides/efeitos dos fármacos , Fósforo na Dieta/farmacologia , Ratos , Ratos Wistar , Índice de Gravidade de Doença , Transdução de Sinais/fisiologia , Uremia/fisiopatologia
9.
Nephrol Dial Transplant ; 26(11): 3429-36, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22039012

RESUMO

Vascular calcification, bone loss and increased fracture risk are age-associated disorders. Several epidemiological studies have suggested a relationship between vascular calcification, impaired bone metabolism and increased mortality. So far, this relationship had been under-estimated as osteoporosis and vascular calcification have been considered non-modifiable disorders of aging. Recent data suggest that this association is not simply an artefact of age, stressing that the co-incidence of vascular calcification with low bone activity and osteoporosis could be biologically linked. During the development of vascular calcification, the transition of vascular smooth muscle cells towards an osteoblast-like phenotype promotes the release of the vesicular structures and mineralization within these structures is promoted by several players, including those related to mineral metabolism, like phosphorus, calcium or parathyroid hormone, which influence either the supersaturation within the structure or the expression of osteogenic factors. However, an intriguing question is whether the presence of vascular calcification impacts bone metabolism, thus demonstrating true crosstalk between these tissues. Evidence is now emerging, suggesting that some inhibitors of the Wnt pathway, such as secreted frizzled Proteins 2 and 4 and Dickkopf related protein-1 (DKK-1), may play a role linking vascular calcification and bone loss. An additional important question to answer, from the patient's perspective, is whether or not progression of vascular calcification can be prevented or restricted and whether altering this progression we can efficiently impact patients' outcomes. Much evidence suggests that the control of the chronic kidney disease-mineral and bone disorder components, particularly serum phosphorus, are the main targets to maintain normal bone turnover and protect against vascular calcification.


Assuntos
Osso e Ossos/fisiopatologia , Osteoporose/etiologia , Calcificação Vascular/complicações , Humanos
10.
J Nephrol ; 24(6): 669-72, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21928237

RESUMO

BACKGROUND: Several studies have demonstrated the impact of vascular calcification on morbidity and mortality both in the general and chronic kidney disease populations. The process of vascular calcification involves complex mechanisms including the overexpression of genes and proteins associated with mineralization and increments of reactive oxygen species (ROS). Taking into account previous findings, we decided to analyze in vitro the likely inhibitory effect of natural antioxidants in the process of vascular calcification. METHODS: Primary vascular smooth muscle cells (VSMCs) were cultured with either normal medium or normal medium supplemented with calcium and phosphorus (P + Ca) in combination with several antioxidants. Mineralization, intracellular reactive oxygen species levels and the protein expression of Cbfa1/RUNX2 and Mn-superoxide dismutase-2 (SOD-2) were investigated. RESULTS: Curcumin and silybin were the more effective, inhibiting both ROS increase and VSMC mineralization. Curcumin was able to prevent the increase in Cbfa1/RUNX2 expression, but did not modify SOD-2 expression in the VSMCs cultured with the P + Ca medium. CONCLUSIONS: These findings support the importance of performing further studies in this field, as some antioxidants might have potential benefits in the management of vascular calcification.


Assuntos
Antioxidantes/farmacologia , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Calcificação Vascular/metabolismo , Animais , Antioxidantes/uso terapêutico , Cálcio/farmacologia , Células Cultivadas , Subunidade alfa 1 de Fator de Ligação ao Core/metabolismo , Curcumina/farmacologia , Curcumina/uso terapêutico , Técnicas In Vitro , Músculo Liso Vascular/citologia , Fósforo/farmacologia , Ratos , Ratos Wistar , Silibina , Silimarina/farmacologia , Silimarina/uso terapêutico , Superóxido Dismutase/metabolismo
11.
Med Princ Pract ; 20(3): 203-12, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21454988

RESUMO

Vascular calcification plays a major role in cardiovascular disease, which is one of the main causes of mortality in chronic kidney disease patients. Vascular calcification is determined by prevalent traditional and uraemia-related (non-traditional) risk factors. It occurs mainly in the arteries, which are classified into three types according to their size and structural characteristics. In addition, vascular calcification has been associated with bone loss and fractures in chronic kidney disease patients and the general population, stressing the fact that both disorders can share pathogenetic pathways. The strategies to control vascular calcification involve several measures, chief among them the control of hyperphosphataemia. Furthermore, it has been recently described that strategies that reduce bone resorption and increase bone mineralization may decrease the risk of vascular calcifications; however, this approach still remains controversial. The mechanisms involved in vascular calcification are complex and not yet fully understood. Phosphorus plays a major role, while other factors related to bone formation have been recently identified.


Assuntos
Calcificação Fisiológica , Calcinose/complicações , Hiperparatireoidismo Secundário/complicações , Nefropatias/complicações , Doenças Vasculares/complicações , Calcinose/sangue , Humanos , Hipercalcemia/complicações , Hiperfosfatemia/complicações , Fatores de Risco
12.
Nephrol Dial Transplant ; 25(9): 2930-7, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20233740

RESUMO

BACKGROUND: The aim of this study was to investigate whether nanomolar concentrations of lanthanum could influence the calcium-sensing receptor (CaSR) response. METHODS: Embryonic kidney (HEK-293) cells transiently transfected with the human CaSR were used to test the ability of lanthanum to activate the CaSR, either alone or in combination with calcium. CaSR activation was measured by flow cytometry. Parathyroid glands from 4-month-old male Wistar rats with normal renal function (n = 60) were also cultured ex vivo with different concentrations of lanthanum to measure parathyroid hormone (PTH) secreted to the medium and PTH mRNA. RESULTS: The maximal CaSR activation induced by 1 muM lanthanum chloride (LaCl(3)) was similar to that induced by 16 mM calcium chloride (CaCl(2) 16 mM: 294 +/- 14%; LaCl(3) 1 muM: 303 +/- 11%). Lanthanum half effective concentration (EC(50)) was 77.28 nM, lower than the 2.30 mM obtained for calcium, supporting the concept that this metal is a strong agonist of the CaSR. Moreover, lanthanum was also able to enhance CaSR sensitivity to calcium. The presence of 1 nM LaCl(3) significantly left-shifted the CaSR response curve, changing the EC(50) value for calcium from 2.30 mM (calcium alone) to 1.26 mM (calcium + 1 nM lanthanum). The parathyroid glands cultured with lanthanum showed a trend to secrete less PTH compared to the control glands: 1.51 +/- 0.23 (control), 0.91 +/- 0.17 (La 100 nM) and 1.04 +/- 0.18 (La 400 nM) [(pg/h)/(pg/h), mean +/- SEM] (ANOVA P = 0.0145). A similar trend was also observed in PTH synthesis measured by PTH mRNA levels. CONCLUSIONS: These in vitro findings demonstrate that lanthanum, at nanomolar concentrations, is an agonist of the CaSR able to activate it in the absence of calcium. In addition, it can also enhance CaSR sensitivity to calcium, modulating PTH synthesis and secretion.


Assuntos
Cloreto de Cálcio/farmacologia , Lantânio/farmacologia , Glândulas Paratireoides/efeitos dos fármacos , Receptores de Detecção de Cálcio/metabolismo , Animais , Western Blotting , Células Cultivadas , Sinergismo Farmacológico , Citometria de Fluxo , Humanos , Técnicas Imunoenzimáticas , Rim/citologia , Rim/efeitos dos fármacos , Rim/metabolismo , Masculino , Espectrometria de Massas , Glândulas Paratireoides/citologia , Glândulas Paratireoides/metabolismo , Hormônio Paratireóideo/genética , Hormônio Paratireóideo/metabolismo , RNA Mensageiro/genética , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa
13.
Pediatr Nephrol ; 25(4): 609-16, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20151157

RESUMO

At present, new compounds are available to treat secondary hyperparathyroidism, namely calcimimetics, novel phosphorus binders and also novel vitamin D receptor activators. Calcimimetics increase the sensitivity of the parathyroid gland to calcium through spatial configurational changes of the calcium-sensing receptor. In addition, experimental studies have demonstrated that calcimimetics also upregulate both the calcium-sensing receptor and the vitamin D receptor. They are efficacious in children, though the experience in paediatric chronic kidney disease is still limited. Sevelamer, lanthanum carbonate and magnesium iron hydroxycarbonate are novel phosphorus binders available on the market. Several studies have demonstrated their efficacy and safety up to 6 years, though costs are the main limitation for a wider use. Since almost all the experience available on the new phosphorus binders comes from its use in adults, studies on children are needed in order to confirm the efficacy and safety of these products. Other new salts and polymers are also being developed. New vitamin D receptor activators, such as paricalcitol, are as effective at suppressing parathyroid hormone (PTH) as the traditional vitamin D receptor activators used for the past two decades, but they have a better and safer profile, showing fewer calcaemic and phosphoraemic effects while preserving the desirable effects of the vitamin D receptor activators on the cardiovascular system, hypertension, inflammation and fibrosis. Their use in children with chronic kidney disease has revealed similar responses to those of adults. The novel compounds discussed in this review should facilitate and improve the management of mineral and bone disorders in children with chronic kidney disease.


Assuntos
Cálcio/uso terapêutico , Hiperparatireoidismo Secundário/tratamento farmacológico , Fosfatos/metabolismo , Receptores de Calcitriol/antagonistas & inibidores , Receptores de Detecção de Cálcio/antagonistas & inibidores , Conservadores da Densidade Óssea/uso terapêutico , Cálcio/metabolismo , Quelantes/uso terapêutico , Criança , Cinacalcete , Ergocalciferóis/uso terapêutico , Humanos , Falência Renal Crônica/tratamento farmacológico , Falência Renal Crônica/metabolismo , Naftalenos/uso terapêutico , Glândulas Paratireoides , Poliaminas/uso terapêutico , Ligação Proteica , Receptores de Calcitriol/efeitos dos fármacos , Receptores de Calcitriol/metabolismo , Receptores de Detecção de Cálcio/efeitos dos fármacos , Receptores de Detecção de Cálcio/metabolismo , Sevelamer
14.
Bone ; 46(1): 121-8, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19772957

RESUMO

In chronic kidney disease, hyperphosphatemia has been associated to vascular calcifications. Moreover, the rate and progression of vascular calcification have been related with the reduction of bone mass and osteoporotic fractures, hereby suggesting a strong link between vascular calcification and bone loss. Our aim was to prospectively study the effects of high phosphorus diet on bone mass, vascular calcification and gene expression profile of the arterial wall. A rat model of 7/8 nephrectomy fed with normal (0.6%) and moderately high (0.9%) phosphorus diet was used. Biochemical parameters, bone mineral density and vascular calcifications were assessed. A microarray analysis of the aortic tissue was also performed to investigate the gene expression profile. After 20 weeks, the rats fed with a high phosphorus diet showed a significant increase in serum phosphorus, PTH, and creatinine, together with aortic calcification and a decrease in bone mass. The histological analysis of the vascular calcifications showed areas with calcified tissue and the gene expression profile of this calcified tissue showed repression of muscle-related genes and overexpression of bone-related genes, among them, the secreted frizzled related proteins, well-known inhibitors of the Wnt pathway, involved in bone formation. The study demonstrated prospectively the inverse and direct relationship between vascular calcification and bone mass. In addition, the microarrays findings provide new information on the molecular mechanisms that may link this relationship.


Assuntos
Aorta/metabolismo , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/patologia , Calcinose/induzido quimicamente , Fósforo/efeitos adversos , Doenças Vasculares/induzido quimicamente , Animais , Aorta/efeitos dos fármacos , Densidade Óssea/efeitos dos fármacos , Osso e Ossos/metabolismo , Calcinose/metabolismo , Calcinose/patologia , Densitometria , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/genética , Masculino , Análise de Sequência com Séries de Oligonucleotídeos , Fósforo/administração & dosagem , Ratos , Ratos Wistar , Doenças Vasculares/metabolismo , Doenças Vasculares/patologia
15.
Expert Opin Drug Discov ; 5(3): 265-75, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22823022

RESUMO

IMPORTANCE OF THE FIELD: The current regulation of parathyroid hormone (PTH) and the development of parathyroid disorders in chronic kidney disease involve complex mechanisms. Factors such as calcium, phosphorous, calcitriol, vitamin D receptor, calcium-sensing receptor and fibroblast growth factor 23 play a key role in the regulatory process in the pathogenesis of secondary hyperparathyroidism. AREAS COVERED IN THIS REVIEW: This review provides an analysis of published results related to the different models and approaches used to study the mechanisms involved in the pathogenesis of secondary hyperparathyroidism. The review includes clinical studies, animal and ex vivo/in vitro models which have been extensively used in this area. WHAT THE READER WILL GAIN: Readers will have an overview of the main findings and progress achieved in the knowledge of the parathyroid function combining the results obtained from the different models used to understand the parathyroid gland regulation. TAKE HOME MESSAGE: Each of the available models used to study the complex system of parathyroid regulation has advantages and limitations; therefore, it is necessary to combine the information obtained from more than one model in order to have a more complete knowledge of the mechanisms involved in PTH regulation.

16.
J Am Soc Nephrol ; 20(9): 2009-17, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19628670

RESUMO

The mechanisms by which estrogens modulate PTH are controversial, including whether or not estrogen receptors (ERs) are present in the parathyroid glands. To explore these mechanisms, we combined a rat model of CKD with ovariectomy and exogenous administration of estrogens. We found that estrogen treatment significantly decreased PTH mRNA and serum levels. We did not observe ERalpha or ERbeta mRNA or protein in the parathyroids, suggesting an indirect action of estrogens on PTH regulation. Estrogen treatment significantly decreased serum 1,25(OH)(2) vitamin D(3) and phosphorus levels. In addition, estrogens significantly increased fibroblast growth factor 23 (FGF23) mRNA and serum levels. In vitro, estrogens led to transcriptional and translational upregulation of FGF23 in osteoblast-like cells in a time- and concentration-dependent manner. These results suggest that estrogens regulate PTH indirectly, possibly through FGF23.


Assuntos
Estradiol/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Hiperparatireoidismo Secundário/metabolismo , Glândulas Paratireoides/fisiologia , Hormônio Paratireóideo/metabolismo , Insuficiência Renal Crônica/metabolismo , Animais , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/fisiologia , Linhagem Celular Tumoral , Estradiol/farmacologia , Receptor alfa de Estrogênio/genética , Receptor beta de Estrogênio/genética , Feminino , Fatores de Crescimento de Fibroblastos/genética , Rim/fisiologia , Osteossarcoma , Ovariectomia , Glândulas Paratireoides/efeitos dos fármacos , Hormônio Paratireóideo/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley
17.
Coron Artery Dis ; 20(6): 383-6, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19620856

RESUMO

OBJECTIVES: Inherited and acquired risk factors contribute to the development of the atherosclerotic lesion and its most common clinical manifestation, myocardial infarction (MI). Multiple studies have suggested a role for matrix metalloproteinases (MMPs) in atherosclerosis, and several functional polymorphisms in the MMP-1 gene have been linked to the risk of MI. The aim of this study was to evaluate the association between MMP-1 promoter polymorphisms and early MI in a Spanish cohort. METHODS: We carried out a case-control study with 261 unrelated patients who had suffered an MI before 55 years of age and 194 healthy controls, all male and smokers. The genotypes for the three MMP-1 promoter polymorphisms -1607 1G/2G, -519 A/G, and -340 T/C were determined through PCR-restriction fragment length polymorphism. Allelic, genotypic, and haplotypic frequencies were statistically compared between groups. RESULTS: Frequencies of the three polymorphisms did not differ between patients and controls. The -1607 1G/2G and -519 A/G variants were in linkage disequilibrium. Analysis of the haplotype frequencies showed significant associations of the 2G(-1607)-G(-519)-T(-340) (odds ratio = 2.40; 95% confidence interval = 1.27-4.55; P<0.006) and 1G(-1607)-G(-519)-T(-340) (odds ratio = 0.68; 95% confidence interval = 0.50-0.94; P<0.05) haplotypes with the risk of early MI. CONCLUSION: MMP-1 promoter polymorphisms are associated with the risk of early MI in a Spanish population of smoking males.


Assuntos
Metaloproteinase 1 da Matriz/genética , Infarto do Miocárdio/genética , Polimorfismo Genético , Regiões Promotoras Genéticas , Adulto , Estudos de Casos e Controles , Frequência do Gene , Predisposição Genética para Doença , Haplótipos , Humanos , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/enzimologia , Razão de Chances , Medição de Risco , Fatores de Risco , Fatores Sexuais , Fumar/efeitos adversos , Espanha
19.
Nephrol Dial Transplant ; 23(11): 3479-84, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18556746

RESUMO

BACKGROUND: The regulatory mechanisms of parathyroid hormone (PTH) synthesis are complex, involving calcium, calcitriol, the calcium-sensing receptor (CaR) and the vitamin D receptor (VDR). In this study, the effects of calcium and calcitriol on the simultaneous expression of CaR and VDR mRNA and protein levels were assessed in parathyroid glands cultured in vitro. METHODS: Parathyroid glands (N = 424) were removed and cultured for 24 h to study the effect of calcium on the CaR, VDR and PTH. In addition, the effect of calcitriol at low calcium concentrations (0.6 mM) on CaR and VDR levels was studied after 48 h of incubation. CaR, VDR and PTH mRNAs were measured by quantitative real-time PCR (qRT-PCR), and CaR and VDR protein levels were measured by immunohistochemistry. RESULTS: PTH gene expression was reduced by high calcium concentration. No differences were found in the CaR mRNA levels among the different calcium concentrations tested (0.6 mM calcium: 100%; 1.2 mM calcium: 120%; 2.0 mM calcium: 112%; median values), but VDR gene expression rose when calcium increased (0.6 mM calcium: 100%; 1.2 mM calcium: 164%; 2.0 mM calcium: 195%; median values). Calcitriol increased both CaR (control: 100%; 10(-8) M calcitriol: 196%; median values) and VDR genes expression (control: 100%; 10(-8) M calcitriol: 176%; median values). The same findings were corroborated at protein levels for both CaR and VDR. CONCLUSIONS: In parathyroid glands cultured in vitro, calcium up-regulates VDR but not CaR. Conversely, calcitriol up-regulates both VDR and CaR mRNAs and protein levels, even at low calcium concentrations.


Assuntos
Calcitriol/fisiologia , Cálcio/fisiologia , Glândulas Paratireoides/metabolismo , Receptores de Calcitriol/metabolismo , Receptores de Detecção de Cálcio/metabolismo , Animais , Masculino , Modelos Animais , Técnicas de Cultura de Órgãos , Hormônio Paratireóideo/metabolismo , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...